Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3.

scientific article published on 13 March 2007

Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3. is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1028994264
P356DOI10.1186/1742-6405-4-6
P932PMC publication ID1828738
P698PubMed publication ID17352834
P5875ResearchGate publication ID6453953

P50authorSomnuek SungkanuparphQ75156091
P2093author name stringWeerawat Manosuthi
Sirirat Likanonsakul
Sukanya Chimsuntorn
P2860cites workStevens-Johnson syndrome caused by the antiretroviral drug nevirapineQ31928274
Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysisQ34093134
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patientsQ34191241
The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.Q39525270
Clinical experience with non-nucleoside reverse transcriptase inhibitors.Q41694988
Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapyQ43672041
High hepatotoxicity rate seen among HAART patientsQ43730857
Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugsQ44198482
Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosisQ44323557
Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.Q44365647
A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patientsQ44620199
Hepatotoxicity associated with nevirapine use.Q44799933
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyQ44849439
Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or lessQ44997968
Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week studyQ45134803
Severe hepatotoxicity associated with nevirapine use in HIV-infected subjectsQ45270618
Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infectionQ45751686
Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean countryQ47298369
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panelQ50105738
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).Q53851252
Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort StudyQ57075689
Predictors of optimal virological response to potent antiretroviral therapyQ73064663
DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapyQ77595515
Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicinQ79738909
Initiation of highly active antiretroviral therapy in advanced AIDS with CD4 < 50 cells/mm3 in a resource-limited setting: efficacy and tolerabilityQ81647605
Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohortQ83323867
P921main subjectnevirapineQ263713
lamivudineQ422631
stavudineQ423984
anti-retroviral agentQ50430310
P304page(s)6
P577publication date2007-03-13
P1433published inAIDS Research and TherapyQ15755474
P1476titleSafety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3.
P478volume4